Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.

ABSTRACT:

Background and objective

Type 2 (T2) innate lymphoid cells (ILC2s) contribute to airway inflammation and disease in asthma. We hypothesize that ILC2s isolated from people with severe allergic and eosinophilic asthma would exhibit an enhanced T2 inflammatory activity that would be altered following treatment with mepolizumab and omalizumab. We compare peripheral blood (PB) isolated ILC2's proliferative capacity, IL-5 and IL-13 secretion and phenotype between healthy without asthma (HC), non-asthma allergic (NAA), mild asthma (MA) and severe allergic and eosinophilic asthma (SA) subjects. We then determined the impact of 6 months treatment with either mepolizumab or omalizumab on ILC2s physiology of SA subjects.

Methods

ILC2s were sorted and cultured in the presence of IL-2, I

SUBMITTER: Malik B 

PROVIDER: S-EPMC10946917 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature